HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Claims Continue Attracting Federal Enforcement Actions

This article was originally published in The Tan Sheet

Executive Summary

Herbal and supplement products allegedly making deceptive cancer cure claims prompted the Federal Trade Commission to file complaints against 11 firms, including five that rejected settlement offers and are contesting the complaints

You may also be interested in...

Herbal Firm Denied Supreme Court Hearing Over Cancer Claim

The Supreme Court will not consider herbal supplement marketer Daniel Chapter One's argument that the right to freedom of religion allows the firm to claim its products cure cancer.

In Brief

Colgate Buys Sanex Deodorants

FTC judge dismisses Gemtronics case

The chief administrative law judge appointed by the Federal Trade Commission dismisses the commission's complaint against Franklin, N.C., firm Gemtronics Inc., and its owner, William Isely, because FTC did not adequately prove that Isely or the firm was responsible for deceptive advertising of an herbal remedy advertised falsely as a cancer cure. Isely admitted to selling the product RAAX11, which was "promoted as a mixture of chrysobalanus icaco, a derivative from a tropical bush, and agaricus, a medicinal mushroom," according to FTC, but he denied advertising or selling the product through 1www.agaricus.net, the Web site where the offending claims appeared. FTC has 30 days from Sept. 16 to appeal. FTC charged Gemtronics and Isely with making deceptive and false claims in September 2008 (2"The Tan Sheet" Sept. 22, 2008). The firm was one of 11 challenged under "Operation False Cures," a "law enforcement sweep aimed at peddlers of phony cancer remedies," FTC noted

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts